FDA Approves PADCEV EJFV — SEAGEN INC.

The U.S. FDA has approved the INDICATION for Enfortumab Vedotin (Padcev EJFV) for INITIATED TREATMENT of LOCALIZED MUSCOSAL SQUAMOUS CELL CARCINOMA (UCSCC), DEVELOPED BY SEAGEN INC., SIGNIFYING A POTENTIAL EXPANSION OF THE UROTHELIAL CANCER MARKET AS BIOLOGICS SEEK TO CAPTURE ADDITIONAL TRUE MCPH PATIENTS.